Gravitate Health FHIR Implementation Guide (FHIR R4), published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health-ips/ and changes regularly. See the Directory of published versions
Example Bundle: Cecilia Gravitate's IPS
id:
gravitate-Cecilia
Composition status:
final
Composition Type:
Patient summary Document
Subject:
identifier:
Cecilia-1
Name:
Cecilia Gravitate
active:
true
gender:
female
Birth Date:
1946-05-05
Sections
Problem List
Condition:
COPD - Chronic obstructive pulmonary disease (13645005)
clinicalStatus:
active
asserter:
Dr. Anna Karlsson
Condition:
Congestive heart failure (42343007)
clinicalStatus:
active
asserter:
Dr. Anna Karlsson
onsetDateTime:
2015
Condition:
Osteoporosis (64859006)
clinicalStatus:
active
onsetDateTime:
1993
Condition:
Diabetes mellitus type 2 (44054006)
clinicalStatus:
active
Medication Summary
Medication:
Dimethyl fumarate 30 mg Tablet
status:
active
Medication Detail:
-
System
https://spor.ema.europa.eu/pmswi
Code:
EU/1/17/1201/002 [Skilarence 120 mg gastro-resistant tablets]
-
System
https://www.who-umc.org/phpid
Code:
0x9982CA8A825D4561506CE808982E3B9D [dimethyl fumarate, 30 mg/ 1 tablet, Gastro-resistant tablet]
-
System
http://www.whocc.no/atc
Code:
L04AX07 [dimethyl fumarate]
Dose Form:
Gastro-resistant tablet
Ingredient:
dimethyl fumarate (http://fdasis.nlm.nih.gov#FO2303MNI2)
strength:
30 mg/1 Tablet
Route:
Oral use
Medication:
Irbesartan 75 mg Tablet
status:
active
Medication Detail:
-
System
https://spor.ema.europa.eu/pmswi
Code:
EU/1/97/049/001 [Karvea 75 mg/ 1 tablet, Tablet]
-
System
http://www.whocc.no/atc
Code:
C09DA04 [irbesartan and diuretics]
Dose Form:
Tablet
Ingredient:
irbesartan (http://fdasis.nlm.nih.gov#J0E2756Z7N)
strength:
75 mg/1 Tablet
Route:
Oral use
Medication:
Oxymetazoline hydrochloride 0.05 mg / 1 ml Spray
status:
active
Medication Detail:
-
System
https://spor.ema.europa.eu/pmswi
Code:
16028/0340 [Boots Decongestant 0.05% w/v Nasal spray]
-
System
https://www.who-umc.org/phpid
Code:
0xF79CABF272B6A7EEF104DDDA44E82234 [Oxymetazoline hydrochloride, 0.5 mg/ 1 ml, Nasal spray, solution]
-
System
http://www.whocc.no/atc
Code:
R01AA05 [oxymetazoline]
Dose Form:
Nasal spray, solution
Ingredient:
oxymetazoline hydrochloride (http://fdasis.nlm.nih.gov#K89MJ0S5VY)
strength:
0.05 mg/1
Route:
Nasal use
Medication:
Oxymetazoline hydrochloride 0.05 mg / 1 ml Spray
status:
active
Medication Detail:
-
System
https://spor.ema.europa.eu/pmswi
Code:
16028/0340 [Boots Decongestant 0.05% w/v Nasal spray]
-
System
https://www.who-umc.org/phpid
Code:
0xF79CABF272B6A7EEF104DDDA44E82234 [Oxymetazoline hydrochloride, 0.5 mg/ 1 ml, Nasal spray, solution]
-
System
http://www.whocc.no/atc
Code:
R01AA05 [oxymetazoline]
Dose Form:
Nasal spray, solution
Ingredient:
oxymetazoline hydrochloride (http://fdasis.nlm.nih.gov#K89MJ0S5VY)
strength:
0.05 mg/1
Route:
Nasal use
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
